Table 1.
Baseline characteristics of 189 breast cancer patients with brain metastases
| Characteristics | Total N=189 (%) |
|---|---|
| Median age (range) | |
| at initial diagnosis of distant metastasis | 46 (25–85) |
| at initial diagnosis of BM | 48 (26–87) |
| Menopausal status at initial diagnosis | |
| premenopausal | 104 (55%) |
| postmenopausal | 42 (22%) |
| unknown | 43 (23%) |
| Histology | |
| Invasive ductal carcinoma | 163 (86%) |
| Invasive lobular carcinoma | 3 (2%) |
| Others | 10 (5%) |
| Unknown | 13 (7%) |
| Stage at initial diagnosis | |
| I/II | 81 (43%) |
| III | 76 (40%) |
| IV | 18 (10%) |
| unknown | 14 (7%) |
| Tumor subtype | |
| HR-positive/HER2-negative | 45 (23%) |
| HER2-positive irrespective of HR status | 86 (47%) |
| TNBC | 58 (31%) |
| AntiHER2 Treatment among HER2-positive patients (N=86) | |
| Before BM diagnosis | 47 (51%) |
| as an adjuvant treatment | 12 |
| as a neoadjuvant treatment | 1 |
| as a palliative treatment | 34 |
| After BM diagnosis | 15 (17%) |
| No anti-HER2 treatment | 24 (32%) |
| Overall Survival, median months | |
| from initial distant metastases (mOS) | 23.3 |
| from initial BM diagnosis (BM-OS) | 9.6 |